Perrigo Company plc (0Y5E.L)
USD 26.0
(-2.11%)
USD 26.0
(-2.11%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.07 Billion USD | -0.81% |
| 2022 | 4.1 Billion USD | 16.65% |
| 2021 | 3.52 Billion USD | -1.28% |
| 2020 | 3.56 Billion USD | 5.84% |
| 2019 | 3.36 Billion USD | 3.91% |
| 2018 | 3.24 Billion USD | -2.96% |
| 2017 | 3.34 Billion USD | -42.37% |
| 2016 | 5.79 Billion USD | 9.15% |
| 2015 | 5.31 Billion USD | 64.23% |
| 2014 | 3.23 Billion USD | 63.84% |
| 2013 | 1.97 Billion USD | 44.16% |
| 2012 | 1.36 Billion USD | 53.38% |
| 2011 | 892.77 Million USD | -33.57% |
| 2010 | 1.34 Billion USD | 50.64% |
| 2009 | 892.18 Million USD | -2.51% |
| 2008 | 915.19 Million USD | 35.0% |
| 2007 | 677.91 Million USD | 5.63% |
| 2006 | 641.79 Million USD | -5.82% |
| 2005 | 681.47 Million USD | 7052.32% |
| 2004 | 9.52 Million USD | 6.1% |
| 2003 | 8.98 Million USD | 7.7% |
| 2002 | 8.33 Million USD | -34.65% |
| 2001 | 12.75 Million USD | 43.62% |
| 2000 | 8.88 Million USD | -93.74% |
| 1999 | 142 Million USD | 63.22% |
| 1998 | 87 Million USD | 4733.33% |
| 1997 | 1.8 Million USD | -96.33% |
| 1996 | 49.1 Million USD | -50.6% |
| 1995 | 99.4 Million USD | 35.79% |
| 1994 | 73.2 Million USD | -3.68% |
| 1993 | 76 Million USD | 62.05% |
| 1992 | 46.9 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.24 Billion USD | 4.2% |
| 2024 Q2 | 4.25 Billion USD | 0.15% |
| 2023 Q1 | 4.1 Billion USD | -4.53% |
| 2023 FY | 4.07 Billion USD | -0.81% |
| 2023 Q3 | 4.08 Billion USD | -0.19% |
| 2023 Q2 | 4.09 Billion USD | -0.18% |
| 2023 Q4 | 4.07 Billion USD | -0.32% |
| 2022 FY | 4.1 Billion USD | 16.65% |
| 2022 Q3 | 4.11 Billion USD | -0.14% |
| 2022 Q2 | 4.11 Billion USD | 17.12% |
| 2022 Q1 | 3.51 Billion USD | -0.15% |
| 2022 Q4 | 4.29 Billion USD | 4.5% |
| 2021 Q3 | 3.55 Billion USD | -0.16% |
| 2021 Q1 | 3.56 Billion USD | -0.14% |
| 2021 Q4 | 3.52 Billion USD | -0.84% |
| 2021 FY | 3.52 Billion USD | -1.28% |
| 2021 Q2 | 3.55 Billion USD | -0.15% |
| 2020 Q1 | 3.47 Billion USD | 3.01% |
| 2020 Q2 | 4.14 Billion USD | 19.36% |
| 2020 Q4 | 3.56 Billion USD | 0.17% |
| 2020 Q3 | 3.56 Billion USD | -14.06% |
| 2020 FY | 3.56 Billion USD | 5.84% |
| 2019 Q4 | 3.36 Billion USD | -3.74% |
| 2019 Q2 | 3.62 Billion USD | 12.61% |
| 2019 Q1 | 3.21 Billion USD | -0.76% |
| 2019 FY | 3.36 Billion USD | 3.91% |
| 2019 Q3 | 3.5 Billion USD | -3.41% |
| 2018 Q3 | 3.26 Billion USD | -0.54% |
| 2018 Q2 | 3.28 Billion USD | -1.67% |
| 2018 Q4 | 3.24 Billion USD | -0.7% |
| 2018 Q1 | 3.33 Billion USD | -0.08% |
| 2018 FY | 3.24 Billion USD | -2.96% |
| 2017 Q1 | 5.79 Billion USD | -0.05% |
| 2017 FY | 3.34 Billion USD | -42.37% |
| 2017 Q4 | 3.34 Billion USD | -9.52% |
| 2017 Q3 | 3.69 Billion USD | 0.49% |
| 2017 Q2 | 3.67 Billion USD | -36.58% |
| 2016 Q2 | 6.41 Billion USD | -1.71% |
| 2016 Q3 | 5.9 Billion USD | -7.92% |
| 2016 Q4 | 5.79 Billion USD | -1.79% |
| 2016 FY | 5.79 Billion USD | 9.15% |
| 2016 Q1 | 6.52 Billion USD | 8.88% |
| 2015 FY | 5.31 Billion USD | 64.23% |
| 2015 Q3 | 5.37 Billion USD | 1.2% |
| 2015 Q4 | 5.98 Billion USD | 11.44% |
| 2015 Q2 | 5.31 Billion USD | 12.37% |
| 2015 Q1 | 4.72 Billion USD | -1.56% |
| 2014 FY | 3.23 Billion USD | 63.84% |
| 2014 Q2 | 3.23 Billion USD | -1.01% |
| 2014 Q4 | 4.8 Billion USD | 50.42% |
| 2014 Q3 | 3.19 Billion USD | -1.3% |
| 2014 Q1 | 3.26 Billion USD | -1.0% |
| 2013 Q1 | 1.37 Billion USD | 0.36% |
| 2013 FY | 1.97 Billion USD | 44.16% |
| 2013 Q4 | 3.3 Billion USD | 66.4% |
| 2013 Q3 | 1.98 Billion USD | 0.47% |
| 2013 Q2 | 1.97 Billion USD | 43.3% |
| 2012 FY | 1.36 Billion USD | 53.38% |
| 2012 Q4 | 1.37 Billion USD | 0.08% |
| 2012 Q3 | 1.37 Billion USD | 0.15% |
| 2012 Q2 | 1.36 Billion USD | -8.38% |
| 2012 Q1 | 1.49 Billion USD | 0.14% |
| 2011 Q4 | 1.49 Billion USD | 24.43% |
| 2011 Q1 | 891.62 Million USD | 0.07% |
| 2011 Q2 | 892.77 Million USD | 0.13% |
| 2011 Q3 | 1.19 Billion USD | 34.36% |
| 2011 FY | 892.77 Million USD | -33.57% |
| 2010 Q4 | 890.97 Million USD | -1.5% |
| 2010 Q2 | 1.34 Billion USD | 62.91% |
| 2010 Q1 | 825 Million USD | -2.14% |
| 2010 FY | 1.34 Billion USD | 50.64% |
| 2010 Q3 | 904.52 Million USD | -32.7% |
| 2009 Q4 | 843.05 Million USD | 0.01% |
| 2009 Q2 | 892.18 Million USD | 0.15% |
| 2009 Q3 | 842.97 Million USD | -5.52% |
| 2009 Q1 | 890.86 Million USD | -2.01% |
| 2009 FY | 892.18 Million USD | -2.51% |
| 2008 Q1 | 725.36 Million USD | 8.5% |
| 2008 Q3 | 914.59 Million USD | -0.06% |
| 2008 FY | 915.19 Million USD | 35.0% |
| 2008 Q2 | 915.19 Million USD | 26.17% |
| 2008 Q4 | 909.1 Million USD | -0.6% |
| 2007 Q1 | 728.01 Million USD | 5.95% |
| 2007 FY | 677.91 Million USD | 5.63% |
| 2007 Q2 | 677.91 Million USD | -6.88% |
| 2007 Q3 | 669.62 Million USD | -1.22% |
| 2007 Q4 | 668.55 Million USD | -0.16% |
| 2006 Q4 | 687.11 Million USD | 0.45% |
| 2006 Q3 | 684.01 Million USD | 6.58% |
| 2006 Q2 | 641.79 Million USD | 3.29% |
| 2006 Q1 | 621.32 Million USD | -5.28% |
| 2006 FY | 641.79 Million USD | -5.82% |
| 2005 Q3 | 690.11 Million USD | 1.27% |
| 2005 Q4 | 655.93 Million USD | -4.95% |
| 2005 Q2 | 681.47 Million USD | -3.89% |
| 2005 Q1 | 709.04 Million USD | 7166.24% |
| 2005 FY | 681.47 Million USD | 7052.32% |
| 2004 Q2 | 9.52 Million USD | -2.24% |
| 2004 FY | 9.52 Million USD | 6.1% |
| 2004 Q3 | 9.46 Million USD | -0.66% |
| 2004 Q4 | 9.75 Million USD | 3.1% |
| 2004 Q1 | 9.74 Million USD | 20.19% |
| 2003 Q2 | 8.98 Million USD | 2.73% |
| 2003 Q3 | 7.19 Million USD | -19.92% |
| 2003 Q1 | 8.74 Million USD | -7.69% |
| 2003 FY | 8.98 Million USD | 7.7% |
| 2003 Q4 | 8.1 Million USD | 12.77% |
| 2002 Q4 | 9.46 Million USD | 8.48% |
| 2002 Q2 | 8.33 Million USD | 13.89% |
| 2002 Q1 | 7.32 Million USD | -11.06% |
| 2002 FY | 8.33 Million USD | -34.65% |
| 2002 Q3 | 8.72 Million USD | 4.69% |
| 2001 Q4 | 8.23 Million USD | -72.89% |
| 2001 Q3 | 30.35 Million USD | 137.94% |
| 2001 Q2 | 12.75 Million USD | 26.34% |
| 2001 Q1 | 10.09 Million USD | 15.71% |
| 2001 FY | 12.75 Million USD | 43.62% |
| 2000 FY | 8.88 Million USD | -93.74% |
| 2000 Q2 | 8.88 Million USD | -74.15% |
| 2000 Q1 | 34.37 Million USD | -64.53% |
| 2000 Q4 | 8.72 Million USD | 4.83% |
| 2000 Q3 | 8.32 Million USD | -6.28% |
| 1999 FY | 142 Million USD | 63.22% |
| 1999 Q3 | 122.4 Million USD | -13.8% |
| 1999 Q4 | 96.9 Million USD | -20.83% |
| 1999 Q2 | 142 Million USD | -17.25% |
| 1999 Q1 | 171.6 Million USD | -4.24% |
| 1998 Q4 | 179.2 Million USD | 29.2% |
| 1998 Q3 | 138.7 Million USD | 59.43% |
| 1998 FY | 87 Million USD | 4733.33% |
| 1998 Q2 | 87 Million USD | 34.26% |
| 1998 Q1 | 64.8 Million USD | 5.54% |
| 1997 Q4 | 61.4 Million USD | 165.8% |
| 1997 FY | 1.8 Million USD | -96.33% |
| 1997 Q3 | 23.1 Million USD | 1183.33% |
| 1997 Q2 | 1.8 Million USD | 0.0% |
| 1997 Q1 | 1.8 Million USD | -84.75% |
| 1996 FY | 49.1 Million USD | -50.6% |
| 1996 Q1 | 68.1 Million USD | -32.04% |
| 1996 Q2 | 49.1 Million USD | -27.9% |
| 1996 Q3 | 42.1 Million USD | -14.26% |
| 1996 Q4 | 11.8 Million USD | -71.97% |
| 1995 Q3 | 98.4 Million USD | -1.01% |
| 1995 Q2 | 99.4 Million USD | -1.0% |
| 1995 Q1 | 100.4 Million USD | 21.4% |
| 1995 FY | 99.4 Million USD | 35.79% |
| 1995 Q4 | 100.2 Million USD | 1.83% |
| 1994 Q4 | 82.7 Million USD | 5.89% |
| 1994 FY | 73.2 Million USD | -3.68% |
| 1994 Q1 | 75.3 Million USD | -16.8% |
| 1994 Q2 | 73.2 Million USD | -2.79% |
| 1994 Q3 | 78.1 Million USD | 6.69% |
| 1993 Q3 | 77.8 Million USD | 2.37% |
| 1993 FY | 76 Million USD | 62.05% |
| 1993 Q1 | 78.2 Million USD | 27.36% |
| 1993 Q2 | 76 Million USD | -2.81% |
| 1993 Q4 | 90.5 Million USD | 16.32% |
| 1992 Q3 | 61.7 Million USD | 31.56% |
| 1992 Q1 | 42 Million USD | 20900.0% |
| 1992 FY | 46.9 Million USD | 0.0% |
| 1992 Q2 | 46.9 Million USD | 11.67% |
| 1992 Q4 | 61.4 Million USD | -0.49% |
| 1991 Q4 | 200 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -11049.004% |
| Dynavax Technologies Corporation | 256.91 Million USD | -1485.511% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -9709.04% |
| Illumina, Inc. | 2.26 Billion USD | -80.08% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 88.334% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -407240.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 57.364% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 71.377% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -2244.362% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -50.705% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -14992.256% |
| Waters Corporation | 2.35 Billion USD | -72.93% |
| Biogen Inc. | 7.33 Billion USD | 44.49% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -10590.216% |
| Evolus, Inc. | 126.54 Million USD | -3118.909% |
| Adicet Bio, Inc. | 17.7 Million USD | -22909.659% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -9336.375% |
| bluebird bio, Inc. | 330.32 Million USD | -1133.145% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -653.013% |
| FibroGen, Inc. | 170.45 Million USD | -2289.722% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -48.936% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -19404.667% |
| Homology Medicines, Inc. | 44.05 Million USD | -9146.379% |
| Geron Corporation | 85.89 Million USD | -4642.081% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | -69.865% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -815.249% |
| Myriad Genetics, Inc. | 145 Million USD | -2709.241% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -323185.714% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -3431.462% |
| Zoetis Inc. | 6.8 Billion USD | 40.123% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -92435.211% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -87.907% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -259.246% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -403.884% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -11114.382% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -180.24% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -6938.637% |
| Verastem, Inc. | 41.55 Million USD | -9701.959% |
| Nektar Therapeutics | 230.4 Million USD | -1667.961% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -2085.629% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -132411.386% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -191.622% |
| OPKO Health, Inc. | 326.56 Million USD | -1147.351% |
| Exelixis, Inc. | 189.94 Million USD | -2044.527% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -850.84% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -2697515.894% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -2843.017% |
| Imunon, Inc. | 1.13 Million USD | -357437.525% |
| Blueprint Medicines Corporation | 774.12 Million USD | -426.196% |
| Insmed Incorporated | 1.2 Billion USD | -238.324% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -171.696% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -7047.821% |
| TG Therapeutics, Inc. | 110.79 Million USD | -3576.52% |
| Incyte Corporation | 38.28 Million USD | -10539.12% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -364.205% |